Evidence map›Paper›PMID 27552154›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2017

MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.

Giulia Calenda, Guillermo Villegas, Patrick Barnable, Claudia Litterst, Keith Levendosky, Agegnehu Gettie, Michael L Cooney, James Blanchard, José A Fernández-Romero, Thomas M Zydowsky and 1 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Giulia Calenda*Population Council, New York, NY; †BioRad Laboratories, Hercules, CA; ‡Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY; and §Tulane National Primate Research Center, Tulane University, Covington, LA.
Guillermo Villegas
Patrick Barnable
Claudia Litterst
Keith Levendosky
Agegnehu Gettie
Michael L Cooney
James Blanchard
José A Fernández-Romero
Thomas M Zydowsky
Natalia Teleshova
Population Council · USBio-Rad (United States) · USRockefeller University · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONSP51RR000164 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI VEAZEY, RONALD S. · 1985 to 2011
$100.1M
Research Training in Experimental Medicine and PathologyT32OD011124 · OD · TULANE UNIVERSITY OF LOUISIANA · PI BLAIR, ROBERT, RAPPAPORT, JAY · 2012 to 2019
$2.7M
NCRR NIH HHS P51 RR000164NIH HHS P51 OD011104NIH HHS T32 OD011124PEPFAR
6 · The paper itself

Abstract

The Population Council's microbicide gel MZC (also known as PC-1005) containing MIV-150 and zinc acetate dihydrate (ZA) in carrageenan (CG) has shown promise as a broad-spectrum microbicide against HIV, herpes simplex virus (HSV), and human papillomavirus. Previous data show antiviral activity against these viruses in cell-based assays, prevention of vaginal and rectal simian-human immunodeficiency virus reverse transcriptase (SHIV-RT) infection, and reduction of vaginal HSV shedding in rhesus macaques and also excellent antiviral activity against HSV and human papillomavirus in murine models. Recently, we demonstrated that MZC is safe and effective against SHIV-RT in macaque vaginal explants. Here we established models of ex vivo SHIV-RT/HSV-2 coinfection of vaginal mucosa and SHIV-RT infection of rectal mucosa in macaques (challenge of rectal mucosa with HSV-2 did not result in reproducible tissue infection), evaluated antiviral activity of MZC, and compared quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay readouts for monitoring SHIV-RT infection. MZC (at nontoxic dilutions) significantly inhibited SHIV-RT in vaginal and rectal mucosas and HSV-2 in vaginal mucosa when present during viral challenge. Analysis of SHIV-RT infection and MZC activity by 1-step simian immunodeficiency virus gag quantitative RT-PCR and p27 enzyme-linked immunosorbent assay demonstrated similar virus growth dynamics and MZC activity by both methods and higher sensitivity of quantitative RT-PCR. Our data provide more evidence that MZC is a promising dual compartment multipurpose prevention technology candidate.

Indexed as

AnimalsAntiviral AgentsFemaleGelsHerpesvirus 2, HumanMacacaMicrobial Sensitivity TestsModels, TheoreticalMucous MembraneOrgan Culture TechniquesPyridinesRectumRNA-Directed DNA PolymeraseSimian Immunodeficiency VirusUreaVaginaAntiviral AgentsGelsMIV 150PyridinesRNA-Directed DNA PolymeraseUrea

Identifiers

PMID27552154
PMCPMC5303173
OpenAlexW2510572404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.